Medy-Tox (A086900) Stock Overview
Operates as a biopharmaceutical company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
A086900 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Medy-Tox Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩124,900.00 |
| 52 Week High | ₩182,700.00 |
| 52 Week Low | ₩113,100.00 |
| Beta | 0.26 |
| 1 Month Change | 4.78% |
| 3 Month Change | 4.08% |
| 1 Year Change | 3.82% |
| 3 Year Change | -7.41% |
| 5 Year Change | 12.96% |
| Change since IPO | 919.32% |
Recent News & Updates
Why Medy-Tox's (KOSDAQ:086900) Earnings Are Better Than They Seem
Nov 20
Medy-Tox (KOSDAQ:086900) Seems To Use Debt Quite Sensibly
Nov 14Revenues Working Against Medy-Tox Inc.'s (KOSDAQ:086900) Share Price Following 26% Dive
Aug 12Recent updates
Why Medy-Tox's (KOSDAQ:086900) Earnings Are Better Than They Seem
Nov 20Medy-Tox (KOSDAQ:086900) Seems To Use Debt Quite Sensibly
Nov 14Revenues Working Against Medy-Tox Inc.'s (KOSDAQ:086900) Share Price Following 26% Dive
Aug 12Here's Why Medy-Tox (KOSDAQ:086900) Can Manage Its Debt Responsibly
May 16Investors Appear Satisfied With Medy-Tox Inc.'s (KOSDAQ:086900) Prospects As Shares Rocket 26%
Apr 24We Think Medy-Tox's (KOSDAQ:086900) Robust Earnings Are Conservative
Mar 30Lacklustre Performance Is Driving Medy-Tox Inc.'s (KOSDAQ:086900) 27% Price Drop
Nov 18Medy-Tox Inc. (KOSDAQ:086900) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Jul 19Medy-Tox's (KOSDAQ:086900) Anemic Earnings Might Be Worse Than You Think
Mar 31Medy-Tox Inc.'s (KOSDAQ:086900) Prospects Need A Boost To Lift Shares
Feb 27Tread With Caution Around Medy-Tox Inc.'s (KOSDAQ:086900) 0.4% Dividend Yield
Apr 02A Look At Medy-Tox's (KOSDAQ:086900) Share Price Returns
Feb 09
Read This Before Buying Medy-Tox Inc. (KOSDAQ:086900) For Its Dividend
Dec 18Shareholder Returns
| A086900 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.3% | -5.8% | 3.3% |
| 1Y | 3.8% | 38.7% | 89.2% |
Return vs Industry: A086900 underperformed the KR Biotechs industry which returned 38.7% over the past year.
Return vs Market: A086900 underperformed the KR Market which returned 89.2% over the past year.
Price Volatility
| A086900 volatility | |
|---|---|
| A086900 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A086900 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086900's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 718 | Hyun-Ho Jung | www.medytox.com |
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials.
Medy-Tox Inc. Fundamentals Summary
| A086900 fundamental statistics | |
|---|---|
| Market cap | ₩876.77b |
| Earnings (TTM) | ₩21.84b |
| Revenue (TTM) | ₩241.80b |
Is A086900 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086900 income statement (TTM) | |
|---|---|
| Revenue | ₩241.80b |
| Cost of Revenue | ₩101.98b |
| Gross Profit | ₩139.81b |
| Other Expenses | ₩117.97b |
| Earnings | ₩21.84b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.11k |
| Gross Margin | 57.82% |
| Net Profit Margin | 9.03% |
| Debt/Equity Ratio | 16.0% |
How did A086900 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 22:42 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medy-Tox Inc. is covered by 26 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyeryeong Kim | CGS International |
| Sanjeev Rana | CLSA |
| null null | CLSA |